These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 22537594)

  • 1. The future is now in community-acquired pneumonia: cardiovascular complications and conjugate vaccines.
    Aspa J
    Arch Bronconeumol; 2012 Oct; 48(10):347-8. PubMed ID: 22537594
    [No Abstract]   [Full Text] [Related]  

  • 2. [Recommendations for guideline directed vaccination strategy].
    MMW Fortschr Med; 2016 May; 158(9):68-9. PubMed ID: 27333624
    [No Abstract]   [Full Text] [Related]  

  • 3. Association between pneumococcal vaccination and cardiovascular outcomes: a systematic review and meta-analysis of cohort studies.
    Vlachopoulos CV; Terentes-Printzios DG; Aznaouridis KA; Pietri PG; Stefanadis CI
    Eur J Prev Cardiol; 2015 Sep; 22(9):1185-99. PubMed ID: 25252595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential role of 13-valent pneumococcal conjugate vaccine in preventing respiratory complications in bacteraemic pneumococcal community-acquired pneumonia.
    Sanz-Herrero F; Gimeno-Cardona C; Tormo-Palop N; Fernández-Fabrellas E; Briones ML; Cervera-Juan Á; Blanquer-Olivas J
    Vaccine; 2016 Apr; 34(15):1847-52. PubMed ID: 26845737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pneumococcal pneumonia highly probable in immunized children cared for in-group settings].
    Gendrel D; Vallet C; Gelmetti C; Moulin F; Brasme JF; Chalumeau M; Cohen R; Raymond J
    Arch Pediatr; 2010 Apr; 17(4):373-7. PubMed ID: 20189361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In brief: PCV13 for adults 65 years and older.
    Med Lett Drugs Ther; 2014 Oct; 56(1453):102. PubMed ID: 25296261
    [No Abstract]   [Full Text] [Related]  

  • 7. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.
    Bonten MJ; Huijts SM; Bolkenbaas M; Webber C; Patterson S; Gault S; van Werkhoven CH; van Deursen AM; Sanders EA; Verheij TJ; Patton M; McDonough A; Moradoghli-Haftvani A; Smith H; Mellelieu T; Pride MW; Crowther G; Schmoele-Thoma B; Scott DA; Jansen KU; Lobatto R; Oosterman B; Visser N; Caspers E; Smorenburg A; Emini EA; Gruber WC; Grobbee DE
    N Engl J Med; 2015 Mar; 372(12):1114-25. PubMed ID: 25785969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pneumococcal vaccines and the prevention of community-acquired pneumonia.
    Esposito S; Principi N
    Pulm Pharmacol Ther; 2015 Jun; 32():124-9. PubMed ID: 24607597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pneumococcal diagnosis and serotypes in childhood community-acquired pneumonia.
    Elemraid MA; Sails AD; Thomas MF; Rushton SP; Perry JD; Eltringham GJ; Spencer DA; Eastham KM; Hampton F; Gennery AR; Clark JE;
    Diagn Microbiol Infect Dis; 2013 Jun; 76(2):129-32. PubMed ID: 23537785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of pro-adrenomedullin for identifying adverse outcomes in community-acquired pneumonia.
    España PP; Capelastegui A; Mar C; Bilbao A; Quintana JM; Diez R; Esteban C; Bereciartua E; Unanue U; Uranga A
    J Infect; 2015 May; 70(5):457-66. PubMed ID: 25499199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A tale of 2 pneumococcal vaccines.
    Klugman KP
    Clin Infect Dis; 2014 Apr; 58(7):925-7. PubMed ID: 24532545
    [No Abstract]   [Full Text] [Related]  

  • 12. Direct and indirect effects of the 13-valent pneumococcal conjugate vaccine administered to infants and young children.
    Esposito S; Principi N;
    Future Microbiol; 2015; 10(10):1599-607. PubMed ID: 26439470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Biomarkers in community acquired pneumonia - what did we learn from the CAPNETZ study?].
    Krüger S; Pletz MW; Rohde G
    Pneumologie; 2011 Feb; 65(2):110-3. PubMed ID: 21117019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pneumococcal vaccines for older adults: getting the timing right.
    Campos-Outcalt D
    J Fam Pract; 2014 Dec; 63(12):730-3. PubMed ID: 25486320
    [No Abstract]   [Full Text] [Related]  

  • 15. [Important: Pneumococcal protection for older people].
    Heppner HJ
    MMW Fortschr Med; 2024 Mar; 166(5):22-25. PubMed ID: 38514542
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of procalcitonin and C-reactive protein to evaluate vaccine efficacy against pneumonia.
    Madhi SA; Heera JR; Kuwanda L; Klugman KP
    PLoS Med; 2005 Feb; 2(2):e38. PubMed ID: 15736995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review: In COPD, injectable polyvalent pneumococcal vaccines reduce risk for community-acquired pneumonia.
    Stanbrook MB
    Ann Intern Med; 2017 May; 166(10):JC52. PubMed ID: 28505636
    [No Abstract]   [Full Text] [Related]  

  • 18. Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged > or =65 years in the Netherlands.
    Rozenbaum MH; Hak E; van der Werf TS; Postma MJ
    Clin Ther; 2010 Aug; 32(8):1517-32. PubMed ID: 20728764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pneumococcal vaccination in adults.
    Rashid H; Shafi S; Haworth E; Booy R
    Arch Intern Med; 2008 Mar; 168(6):666-7. PubMed ID: 18362261
    [No Abstract]   [Full Text] [Related]  

  • 20. Preventing pneumococcal infections in older adults.
    Nuorti P; Reingold A
    Lancet Respir Med; 2015 Nov; 3(11):834-6. PubMed ID: 26607821
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.